异动解读 | GHRS盘中暴跌22%,新药研发资金短缺成主因

异动解读
05 Feb

爱尔兰生物技术公司GH Research PLC(GHRS.O)当日盘中大幅下跌22.4%,引发市场高度关注。

此前,该公司新的抑郁症治疗药物GH001在中期临床试验中取得阶段性成功,令GHRS股价在周一大涨70%至收盘价17.99美元。不过,新一批临床试验和后续药物研发将需要大量资金投入。

为了筹集研发资金,GHRS公司周一晚间启动了1.5亿美元的新股发行计划。这一新增股份供给预计将引发当前股价的回调调整。由此带来的市场供给压力或许正是GHRS当日暴跌的主要原因所在。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10